Skip to main content
Log in

Powder properties and their influence on dry powder inhaler delivery of an antitubercular drug

  • Published:
AAPS PharmSciTech Aims and scope Submit manuscript

Abstract

The purpose of this study was to determine if aerosol delivery of drug loaded microparticles to lungs infected withMycobacterium tuberculosis may be achieved by predicting dispersion of dry powders through knowledge of particle surface properties. Particle sizes of rifampicin-loaded poly(lactide-co-glycolide) microparticles (R-PLGA), rifampicin alone, and lactose and maltodextrin carrier particles (bulk and 75-125-μm sieved fractions) were determined by electron microscopy for the projected area diameter (Dp) and laser diffraction for the volume diameter (Dv). Surface energies (Y) of R-PLGA, rifampicin alone, lactose, and maltodextrin were obtained by inverse phase gas chromatography, surface areas (Sa) by N2 adsorption, and cohesive energy densities by calculation. Particle dispersion was evaluated (Andersen nonviable impactor) for 10% blends of R-PLGA and rifampicin alone with bulk and sieved fractions of the carriers. Dp for R-PLGA and rifampicin alone was 3.02 and 2.83 μm, respectively. Dv was 13±1 and 2±1 μm for R-PLGA and rifampicin alone, respectively, indicating that R-PLGA was more aggregated. This was evident in Y of 35±1 and 19±6 mJ/m2 for R-PLGA and rifampicin alone. Dp for lactose and maltodextrin (sieved and bulk) was approximately 40 mm. Bulk maltodextrin (Dv=119±6 mm) was more aggregated than bulk lactose (Dv=54±2 mm). This was a result of the higher Sa for maltodextrin (0.54 m2/g) than for lactose (0.21 m2/g). The Y of bulk lactose and maltodextrin was 40±4 and 60±6 mJ/m2 and of sieved lactose and maltodextrin was 39±1 and 50±1 mJ/m2. Impaction studies yielded higher fine particle fractions of R-PLGA from sieved lactose, 13%±3%, than from sieved maltodextrin, 7%±1%, at 90 L/min. An expression, based on these data, is proposed as a predictor of drug dispersion from carrier particles.

Delivery of dry powder formulations can be achieved by characterizing particle surfaces and predicting impact on dispersion.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. World Health Organization. World Health Organization Report. Geneva, Switzerland; 2001.

  2. Comstock GW, Cauthen GM. Epidemiology of tuberculosis. In: Reichman LB, Hershfield ES, eds. Tuberculosis: A Comprehensive International Approach. New York, NY: Marcel Dekker; 1993:23–48.

    Google Scholar 

  3. Grosset JH. Bacteriology of tuberculosis. In: Reichman LB, Hershfield ES, eds. Tuberculosis: A Comprehensive International Approach. New York, NY: Marcel Dekker; 1993:49–74.

    Google Scholar 

  4. O Hara P, Hickey AJ. Respirable PLGA microspheres containing rifampicin for the treatment of tuberculosis: manufacture and characterization. Pharm Res. 2000;17(8):955–961.

    Article  CAS  Google Scholar 

  5. Suarez S, O Hara P, Kazantseva M, et al. Airway delivery of rifampicin microparticles for the treatment of tuberculosis. J Antimicrob Chemother. 2001;48:431–434. [PUBMED]

    Article  PubMed  CAS  Google Scholar 

  6. Suarez S, O Hara P, Kazantseva M, et al. Respirable PLGA microspheres containing rifampicin for the treatment of tuberculosis: screening in an infectious disease model. Pharm Res. 2001;18(9):1315–1319.

    Article  PubMed  CAS  Google Scholar 

  7. Ashurst I, Malton A, Prime D, Sumby B. Latest advances in the development of dry powder inhalers. Pharm Sci Technol Today. 2000;3(7):246–256.

    Article  PubMed  CAS  Google Scholar 

  8. Montreal Protocol. Montreal Protocol on Substances That Deplete Ozone Layer. Washington, DC: US Government Printing Office. 1987;26 ILM 1541.

    Google Scholar 

  9. Dunbar CA, Hickey AJ, Holzner P. Dispersion and Characterization of Pharmaceutical Dry Powder Aerosols. KONA, 1998; 16:7–46.

    CAS  Google Scholar 

  10. Lowell S. Introduction to Powder Surface Area. New York, NY: John Wiley & Sons; 1979.

    Google Scholar 

  11. Fowkes FM. Attractive forces at interfaces. J Ind Eng Chem. 1964;56:40–52.

    Article  CAS  Google Scholar 

  12. Chu B. Molecular Forces. New York, NY: John Wiley & Sons; 1967.

    Google Scholar 

  13. Hancock BC, York P, Rowe RC. The use of solubility parameters in pharmaceutical dosage form design. Int J Pharm. 1997;148:1–21.

    Article  CAS  Google Scholar 

  14. Allen T. Particle Size Measurement. London, England: Chapman and Hall; 1968.

    Google Scholar 

  15. Schultz J, Lavielle L, Martin C. The role of the interface in carbon fibre-epoxy composites. J Adhes. 1987;23:45–60.

    Article  CAS  Google Scholar 

  16. Ticehurst MD, Rowe RC, York P. Determination of the surface properties of two batches of salbutamol sulphate by inverse gas chromatography. Int J Pharm. 1994;111:241–249.

    Article  CAS  Google Scholar 

  17. Dove JW, Buckton G, Doherty C. A comparison of two contact angle measurement methods and inverse gas chromatography to assess the surface energies of theophylline and caffeine. Int J Pharm. 1996;138:199–206.

    Article  CAS  Google Scholar 

  18. Mohammad HAH, Fell JT. Contact angles of powder mixtures consisting of spherical particles. Int J Pharm. 1982;11:149–154.

    Article  Google Scholar 

  19. Newell HE, Buckton G, Butler DA, Thielmann F, Williams DR. The use of inverse phase gas chromatography to study the change of surface energy of amorphous lactose as a function of relative humidity and the processes of collapse and crystallisation. Int J Pharm. 2001;217(1–2):45–56.

    Article  PubMed  CAS  Google Scholar 

  20. Conder JR, Young CL. Physicochemical Measurement by Gas Chromatography. New York, NY: John Wiley & Sons; 1979.

    Google Scholar 

  21. Fedors RF. A method for estimating both the solubility parameters and molar volumes of liquids. Polymer Eng Sci. 1974;14:147–154.

    Article  CAS  Google Scholar 

  22. Van Krevelen DW. Properties of Polymers: Their Estimation and Correlation With Chemical Structure. New York, NY: Elsevier Scientific; 1976.

    Google Scholar 

  23. Clark AR, Hollingworth AM. The relationship between powder inhaler resistance and peak inspiratory conditions in healthy volunteers: implications for in vitro testing. J Aerosol Med. 1993;6(2):99–110. [PUBMED]

    Article  PubMed  CAS  Google Scholar 

  24. Pelizza G, Nebuloni M, Ferrari P, Gallo GG. Polymorphism of rifampicin. Farmaco Edizione Scientifica. 1977;32(7):471–481.

    PubMed  CAS  Google Scholar 

  25. Riddle FLJ, Fowkes FM. Spectral shifts in acid-base chemistry, I: Van der Waals contributions to acceptor numbers. J Am Chem Soc. 1990;112(9):3259–3264.

    Article  CAS  Google Scholar 

  26. Martin A. Physical Pharmacy. 4th ed. Baltimore, MD: Williams & Wilkins; 1993.

    Google Scholar 

  27. Concessio NM, Van Oort MM, Knowles MR, Hickey AJ. Pharmaceutical dry powder aerosols: correlation of powder properties with dose delivery and implications for pharmacodynamic effect. Pharm Res. 1999;16(6):828–834.

    Article  PubMed  CAS  Google Scholar 

  28. Handbook of Pharmaceutical Excipients. Washington, DC: American Pharmaceutical Association; 1986.

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Vasu V. Sethuraman.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Sethuraman, V.V., Hickey, A.J. Powder properties and their influence on dry powder inhaler delivery of an antitubercular drug. AAPS PharmSciTech 3, 28 (2002). https://doi.org/10.1208/pt030428

Download citation

  • Received:

  • Accepted:

  • DOI: https://doi.org/10.1208/pt030428

Keywords

Navigation